• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » U.K. Prime Minister commissions independent antibiotics review

U.K. Prime Minister commissions independent antibiotics review

July 2, 2014
CenterWatch Staff

U.K. Prime Minister David Cameron, along with the U.K. Department of Health, has commissioned a wide reaching independent review, led by economist Jim O’Neill and co-funded and hosted by medical research foundation the Wellcome Trust, to explore the economic issues surrounding antimicrobial resistance. Growing numbers of bacterial and viral infections are resistant to antimicrobial drugs, but no new classes of antibiotics have come on the market for more than 25 years.

Around 25,000 people die each year from infections resistant to antibiotic drugs in Europe alone, and the lack of new drugs capable of fighting bacteria has been described by the World Health Organization as one of the most significant global risks facing modern medicine.

The review will set out a plan for encouraging and accelerating the discovery and development of new generations of antibiotics and will examine:

  • The development, use and regulatory environment of antimicrobials, especially antibiotics, exploring how to make investment in new antibiotics more attractive to pharmaceutical companies and other funding bodies.
  • The balance between effective and sustainable incentives for investment, and the need to conserve antimicrobial drugs so they remain effective for as long as possible.
  • How governments and other funders can stimulate investment in new antimicrobials, and timeframes and mechanisms for implementation.
  • Increasing international cooperation and support for action by the international community, including much closer work with low- and middle-income countries.

O’Neill will work independently of government and will have full freedom to approach the issues and the evidence as he sees fit. He will work with international experts covering all aspects of the AMR pipeline and associated economic issues to identify a range of proposals to form the basis of a new, strengthened global effort.

The announcement comes a week after antimicrobial resistance was chosen by the public as the winner of the $13.6 million Longitude Prize, with a focus on creating a cheap, accurate and easy-to-use test for bacterial infections that will allow doctors and nurses to better target antibiotics and prevent over-use.

Professor Sally Davies, chief medical officer for England, said, “The soaring number of antibiotic-resistant infections poses such a great threat to society that in 20 years’ time we could be taken back to a 19th century environment where everyday infections kill us as a result of routine operations.”

She continued, “We have reached a critical point and must now act on a global scale to slow down antimicrobial resistance. The biotech and pharmaceutical industry will be central to resolving this crisis, which will impact on all areas of modern medicine.”

Dr. Margaret Chan, director general of the World Health Organization, said, “The review will present its initial findings during 2015 with a final report and recommendations to then follow during 2016. This process will run alongside—and engage closely with—the WHO’s development of a Global Action Plan on AMR.”

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing